An improved matrix-type controlled release system for basic fibroblast growth factor.
Basic fibroblast growth factor is an angiogenic polypeptide with potential application in wound healing and surgery. However, its use in these situations has been hampered by its instability in vivo. Controlled release systems have been developed to overcome this, but as yet high yields of basic fibroblast growth factor from a permanent matrix-type device have been elusive. In the present study we describe a device, based on ethylene vinyl acetate copolymer, capable of releasing active basic fibroblast growth factor for at least three weeks. The yield and duration of release of active growth factor from this device is significantly higher than previously reported for devices of this type. This improved yield is made possible by a variation in the production method used for matrix-type devices.
Microsurgery Research Centre, St. Vincent's Hospital, Victoria, Australia.
M J
MJ
Hickey
W A
WA
Morrison
D003692:Delayed-Action Preparations; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000737:chemistry; D006493:Heparin / Q000737:chemistry; D011485:Protein Binding
D003692:Delayed-Action Preparations; D016222:Fibroblast Growth Factor 2; D006493:Heparin